Analysis of clinical trials shows pipeline for therapeutics is small; 99.6 percent of drug attempts fail
Researchers at the Cleveland Clinic Lou Ruvo Center for Brain Health have conducted the first-ever analysis of clinical trials for Alzheimer’s disease (AD), revealing an urgent need to increase the number of agents entering the AD drug development pipeline and progressing successfully towards new therapy treatments. The paper, “Alzheimer’s Disease Drug Development Pipeline: Few Candidates, Frequent Failures,” was published today in the journal Alzheimer’s Research & Therapy.
A comprehensive look at all clinical trials underway shows:
- There are relatively few drugs in development for Alzheimer’s disease.
- The failure rate for AD drug development is 99.6 percent for the decade 2002-2012.
- The number of drugs has been declining since 2009.
“Our goal was to examine historical trends to help understand why Alzheimer’s disease treatment development efforts so often fail,” said Jeffrey L. Cummings, M.D., ScD, Director of the Cleveland Clinic Lou Ruvo Center for Brain Health. “With an estimated 44 million people living worldwide with the condition, the study shows that the Alzheimer’s disease drug development ecosystem needs more support given the magnitude of the problem.”
Read more . . .
The Latest on: Alzheimer’s drug development
[google_news title=”” keyword=”Alzheimer’s drug development” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Alzheimer’s drug development
- Annovis' shares plummet 60% on another failure for lead Alzheimer's medon April 29, 2024 at 8:44 am
Annovis Bio heralded a “significantly higher rate of improvement” in patients with Alzheimer’s disease who received buntanetap. However, digging a little deeper into the muddled readout sugges | ...
- Oasis Or Mirage? Digital Dementia Screening In The Neurology Deserton April 26, 2024 at 12:44 pm
Diagnosis of Alzheimer's and related dementias is broken. As blood tests emerge, what is the role of digital screening tools and neurotechnologies in clinical practice?
- AI helps researchers uncover gut-brain interactions in Alzheimer'son April 26, 2024 at 10:00 am
AI technology reveals more information about the gut-brain health link in Alzheimer's, suggesting new pathways for research around treatments.
- NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summiton April 25, 2024 at 1:10 pm
NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK NK cell therapeutics. NKGen is headquartered in Santa ...
- Alzheimer's drug development pipeline: Positive results, new insight on biomarkers position 2024 as 'learning year'on April 24, 2024 at 12:13 pm
The world of Alzheimer's treatments is at an inflection point as more potential drugs make their way out of clinical trials.
- Alzheimer's drug adoption in US slowed by doctors' skepticismon April 23, 2024 at 10:26 am
Nine months into the U.S. launch of the first drug proven to slow the advance of Alzheimer's, Eisai and Biogen's Leqembi is facing an unexpected hurdle to widespread use: an entrenched belief among ...
- Can supplements really help prevent dementia?on April 23, 2024 at 8:35 am
By 2025, it’s estimated that over one million people in the UK will have a diagnosis of dementia. It’s a sobering thought, but new research suggests that 40 per cent of these cases could be delayed or ...
- Detecting Alzheimer’s disease early through Roche’s breakthrough FDA approved blood teston April 20, 2024 at 4:39 am
A test to detect Alzheimer’s disease earlier is one step closer after receiving the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) ...
- It's the first drug shown to slow Alzheimer's. Why is is it off to a slow start?on April 17, 2024 at 8:30 am
More than 6 million Americans have Alzheimer’s disease, the most common cause of dementia. There’s no cure, but Leqembi clears a sticky brain protein called amyloid.
- How Alzheimer's disease progresses faster in people with Down syndromeon April 17, 2024 at 8:12 am
Nearly all adults with Down syndrome will develop evidence of Alzheimer's disease by late middle age. A new study by researchers at Washington University School of Medicine in St. Louis shows that the ...
via Bing News
